 Kevin Messacar
Concepts (243)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enterovirus Infections | 30 | 2023 | 160 | 10.230 |
Why?
| | Myelitis | 22 | 2024 | 88 | 6.670 |
Why?
| | Enterovirus D, Human | 19 | 2024 | 72 | 6.390 |
Why?
| | Central Nervous System Viral Diseases | 15 | 2024 | 63 | 5.460 |
Why?
| | Neuromuscular Diseases | 15 | 2024 | 89 | 5.320 |
Why?
| | Enterovirus | 13 | 2022 | 72 | 4.120 |
Why?
| | Meningitis | 8 | 2022 | 74 | 4.050 |
Why?
| | Encephalitis | 12 | 2022 | 126 | 3.990 |
Why?
| | Respiratory Tract Infections | 10 | 2023 | 319 | 2.950 |
Why?
| | Disease Outbreaks | 16 | 2023 | 305 | 2.740 |
Why?
| | Anti-Infective Agents | 5 | 2023 | 219 | 2.250 |
Why?
| | Multiplex Polymerase Chain Reaction | 4 | 2020 | 46 | 1.910 |
Why?
| | Nervous System Diseases | 5 | 2020 | 254 | 1.830 |
Why?
| | Paralysis | 5 | 2020 | 66 | 1.710 |
Why?
| | Hospitals, Pediatric | 5 | 2020 | 478 | 1.610 |
Why?
| | Molecular Diagnostic Techniques | 6 | 2020 | 92 | 1.470 |
Why?
| | Cerebrospinal Fluid | 6 | 2019 | 90 | 1.450 |
Why?
| | Central Nervous System Infections | 2 | 2022 | 36 | 1.420 |
Why?
| | Enterovirus A, Human | 2 | 2022 | 12 | 1.400 |
Why?
| | Antimicrobial Stewardship | 4 | 2023 | 92 | 1.320 |
Why?
| | Parechovirus | 3 | 2019 | 7 | 1.300 |
Why?
| | Child | 47 | 2024 | 18401 | 1.290 |
Why?
| | Communicable Diseases | 4 | 2021 | 127 | 1.270 |
Why?
| | Epidemiological Monitoring | 3 | 2021 | 46 | 1.220 |
Why?
| | Picornaviridae Infections | 3 | 2019 | 29 | 1.210 |
Why?
| | Colorado | 20 | 2024 | 4090 | 1.170 |
Why?
| | Anti-Bacterial Agents | 6 | 2024 | 1471 | 1.160 |
Why?
| | Herpesvirus 6, Human | 2 | 2019 | 13 | 1.130 |
Why?
| | Viruses | 4 | 2023 | 94 | 1.070 |
Why?
| | Child, Preschool | 30 | 2024 | 9114 | 1.000 |
Why?
| | Humans | 77 | 2024 | 114045 | 0.900 |
Why?
| | Influenza, Human | 3 | 2020 | 543 | 0.830 |
Why?
| | Respiratory Tract Diseases | 1 | 2024 | 139 | 0.810 |
Why?
| | Simplexvirus | 2 | 2020 | 80 | 0.790 |
Why?
| | Sepsis | 2 | 2018 | 507 | 0.770 |
Why?
| | Nervous System Malformations | 1 | 2022 | 33 | 0.760 |
Why?
| | Brain Diseases | 2 | 2020 | 124 | 0.750 |
Why?
| | Infant | 23 | 2024 | 7943 | 0.750 |
Why?
| | Cranial Nerve Diseases | 3 | 2017 | 42 | 0.730 |
Why?
| | Virus Diseases | 1 | 2022 | 195 | 0.680 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2020 | 40 | 0.670 |
Why?
| | Acyclovir | 1 | 2020 | 100 | 0.670 |
Why?
| | Muscle Hypotonia | 2 | 2020 | 31 | 0.660 |
Why?
| | Exanthema Subitum | 1 | 2019 | 3 | 0.660 |
Why?
| | Hospitals, Teaching | 1 | 2019 | 102 | 0.650 |
Why?
| | Drug Utilization | 2 | 2017 | 164 | 0.650 |
Why?
| | Hepatitis | 1 | 2019 | 45 | 0.640 |
Why?
| | Encephalitis, Viral | 2 | 2020 | 39 | 0.640 |
Why?
| | Taenia solium | 1 | 2018 | 5 | 0.630 |
Why?
| | Neurocysticercosis | 1 | 2018 | 6 | 0.630 |
Why?
| | Abdomen | 1 | 2019 | 99 | 0.630 |
Why?
| | Retrospective Studies | 18 | 2024 | 12521 | 0.630 |
Why?
| | Meningoencephalitis | 2 | 2019 | 24 | 0.620 |
Why?
| | Polymerase Chain Reaction | 6 | 2024 | 990 | 0.610 |
Why?
| | Fluoxetine | 1 | 2018 | 46 | 0.610 |
Why?
| | Gastroenteritis | 1 | 2019 | 65 | 0.610 |
Why?
| | Bacteriological Techniques | 1 | 2018 | 63 | 0.600 |
Why?
| | Hospitalization | 7 | 2020 | 1762 | 0.590 |
Why?
| | Metagenomics | 6 | 2023 | 131 | 0.590 |
Why?
| | Diagnosis, Differential | 6 | 2019 | 1331 | 0.580 |
Why?
| | Seizures | 1 | 2020 | 337 | 0.560 |
Why?
| | Vaccines | 1 | 2022 | 375 | 0.550 |
Why?
| | Antiviral Agents | 2 | 2020 | 642 | 0.540 |
Why?
| | Bacterial Infections | 1 | 2018 | 217 | 0.530 |
Why?
| | Analgesia, Obstetrical | 1 | 2016 | 17 | 0.530 |
Why?
| | Analgesia, Epidural | 1 | 2016 | 20 | 0.530 |
Why?
| | Bacteria | 3 | 2023 | 725 | 0.520 |
Why?
| | Male | 33 | 2024 | 55396 | 0.520 |
Why?
| | Fever | 2 | 2019 | 280 | 0.510 |
Why?
| | Microbial Sensitivity Tests | 1 | 2016 | 300 | 0.500 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 637 | 0.480 |
Why?
| | Health Resources | 1 | 2016 | 120 | 0.470 |
Why?
| | Parotitis | 1 | 2014 | 6 | 0.460 |
Why?
| | Motor Neurons | 1 | 2016 | 213 | 0.460 |
Why?
| | Magnetic Resonance Imaging | 5 | 2020 | 3039 | 0.440 |
Why?
| | Herpesviridae Infections | 1 | 2015 | 138 | 0.440 |
Why?
| | United States | 14 | 2021 | 12137 | 0.420 |
Why?
| | Female | 30 | 2024 | 59324 | 0.410 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2016 | 285 | 0.410 |
Why?
| | Infant, Newborn | 9 | 2019 | 5038 | 0.410 |
Why?
| | Referral and Consultation | 1 | 2017 | 632 | 0.400 |
Why?
| | Quality Improvement | 1 | 2019 | 944 | 0.400 |
Why?
| | Pediatrics | 1 | 2019 | 982 | 0.390 |
Why?
| | High-Throughput Nucleotide Sequencing | 5 | 2023 | 437 | 0.390 |
Why?
| | Brain | 3 | 2018 | 2355 | 0.360 |
Why?
| | Cohort Studies | 6 | 2024 | 4883 | 0.360 |
Why?
| | Seasons | 3 | 2019 | 440 | 0.360 |
Why?
| | Attitude of Health Personnel | 1 | 2017 | 970 | 0.350 |
Why?
| | Internship and Residency | 1 | 2019 | 920 | 0.350 |
Why?
| | Meningitis, Aseptic | 2 | 2020 | 15 | 0.340 |
Why?
| | Genome, Microbial | 2 | 2019 | 7 | 0.290 |
Why?
| | Prospective Studies | 4 | 2024 | 6195 | 0.260 |
Why?
| | Rhinovirus | 2 | 2017 | 40 | 0.240 |
Why?
| | Sequence Analysis, DNA | 5 | 2023 | 722 | 0.240 |
Why?
| | Paraplegia | 2 | 2015 | 52 | 0.240 |
Why?
| | Adolescent | 16 | 2024 | 17800 | 0.230 |
Why?
| | Pleural Effusion | 1 | 2024 | 46 | 0.230 |
Why?
| | Time Factors | 4 | 2018 | 6077 | 0.220 |
Why?
| | Acute Disease | 4 | 2019 | 907 | 0.220 |
Why?
| | Streptococcus pneumoniae | 1 | 2024 | 133 | 0.220 |
Why?
| | Community-Acquired Infections | 1 | 2024 | 139 | 0.210 |
Why?
| | Adenoviridae Infections | 1 | 2023 | 15 | 0.210 |
Why?
| | Arbovirus Infections | 2 | 2020 | 17 | 0.210 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 2023 | 60 | 0.200 |
Why?
| | Respiratory System | 1 | 2023 | 137 | 0.200 |
Why?
| | Liver Failure, Acute | 1 | 2023 | 58 | 0.200 |
Why?
| | Fungi | 1 | 2023 | 124 | 0.200 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2023 | 97 | 0.200 |
Why?
| | Uncertainty | 1 | 2022 | 91 | 0.200 |
Why?
| | Medical Oncology | 1 | 2023 | 229 | 0.190 |
Why?
| | Lung | 1 | 2014 | 3521 | 0.190 |
Why?
| | Hashimoto Disease | 1 | 2021 | 10 | 0.180 |
Why?
| | Brain Abscess | 1 | 2020 | 10 | 0.180 |
Why?
| | Esophageal Perforation | 1 | 2020 | 11 | 0.180 |
Why?
| | Esophageal Fistula | 1 | 2020 | 17 | 0.180 |
Why?
| | Antigens, Viral | 2 | 2019 | 176 | 0.180 |
Why?
| | Meningitis, Viral | 1 | 2020 | 21 | 0.170 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2020 | 19 | 0.170 |
Why?
| | Pandemics | 3 | 2023 | 1310 | 0.170 |
Why?
| | Muscle Weakness | 1 | 2020 | 81 | 0.170 |
Why?
| | HIV Infections | 1 | 2014 | 2453 | 0.170 |
Why?
| | Confusion | 1 | 2020 | 25 | 0.170 |
Why?
| | Immunocompetence | 1 | 2019 | 40 | 0.160 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2019 | 21 | 0.160 |
Why?
| | Seroepidemiologic Studies | 1 | 2019 | 137 | 0.160 |
Why?
| | Myelitis, Transverse | 1 | 2019 | 3 | 0.160 |
Why?
| | Agammaglobulinemia | 1 | 2019 | 30 | 0.160 |
Why?
| | Foreign Bodies | 1 | 2020 | 93 | 0.160 |
Why?
| | Antibodies, Helminth | 1 | 2018 | 6 | 0.160 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2019 | 44 | 0.160 |
Why?
| | Meningitis, Bacterial | 1 | 2019 | 48 | 0.160 |
Why?
| | Canada | 2 | 2019 | 320 | 0.150 |
Why?
| | Body Fluids | 1 | 2018 | 58 | 0.150 |
Why?
| | Leukocyte Count | 1 | 2018 | 292 | 0.150 |
Why?
| | Arboviruses | 1 | 2017 | 10 | 0.150 |
Why?
| | Controlled Before-After Studies | 1 | 2017 | 13 | 0.150 |
Why?
| | Headache | 1 | 2018 | 132 | 0.150 |
Why?
| | Prevalence | 2 | 2015 | 2247 | 0.150 |
Why?
| | RNA | 1 | 2023 | 806 | 0.150 |
Why?
| | Neuromyelitis Optica | 1 | 2019 | 115 | 0.140 |
Why?
| | Program Development | 1 | 2019 | 339 | 0.140 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 87 | 0.140 |
Why?
| | Sensitivity and Specificity | 2 | 2019 | 1690 | 0.140 |
Why?
| | Neoplasms | 2 | 2023 | 2086 | 0.140 |
Why?
| | Refusal to Treat | 1 | 2017 | 18 | 0.140 |
Why?
| | Drug Utilization Review | 1 | 2017 | 56 | 0.140 |
Why?
| | Herpes Simplex | 1 | 2017 | 87 | 0.140 |
Why?
| | Treatment Failure | 1 | 2018 | 330 | 0.140 |
Why?
| | Movement Disorders | 1 | 2017 | 48 | 0.140 |
Why?
| | Electromyography | 2 | 2017 | 326 | 0.140 |
Why?
| | Densovirus | 1 | 2016 | 2 | 0.140 |
Why?
| | Eosinophilia | 1 | 2018 | 186 | 0.140 |
Why?
| | Communicable Disease Control | 1 | 2017 | 67 | 0.140 |
Why?
| | Drug Resistance | 1 | 2017 | 158 | 0.130 |
Why?
| | Muscular Diseases | 1 | 2017 | 104 | 0.130 |
Why?
| | Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2016 | 14 | 0.130 |
Why?
| | Encephalomyelitis | 1 | 2016 | 9 | 0.130 |
Why?
| | Treatment Outcome | 3 | 2019 | 9049 | 0.130 |
Why?
| | Liver Transplantation | 1 | 2023 | 695 | 0.130 |
Why?
| | Balamuthia mandrillaris | 1 | 2015 | 4 | 0.130 |
Why?
| | Amebiasis | 1 | 2015 | 5 | 0.130 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1117 | 0.130 |
Why?
| | Early Diagnosis | 1 | 2016 | 217 | 0.130 |
Why?
| | Genome, Mitochondrial | 1 | 2015 | 27 | 0.130 |
Why?
| | Case-Control Studies | 2 | 2020 | 3003 | 0.120 |
Why?
| | North America | 1 | 2016 | 255 | 0.120 |
Why?
| | Program Evaluation | 1 | 2019 | 820 | 0.120 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2016 | 138 | 0.120 |
Why?
| | Biopsy | 1 | 2018 | 1024 | 0.120 |
Why?
| | Adult | 6 | 2023 | 30375 | 0.120 |
Why?
| | La Crosse virus | 1 | 2014 | 6 | 0.120 |
Why?
| | Kidney | 1 | 2021 | 1182 | 0.120 |
Why?
| | Encephalitis, California | 1 | 2014 | 11 | 0.120 |
Why?
| | Hospitals | 1 | 2019 | 581 | 0.110 |
Why?
| | West Nile Fever | 1 | 2014 | 48 | 0.110 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2019 | 850 | 0.110 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 150 | 0.110 |
Why?
| | Critical Care | 1 | 2017 | 472 | 0.110 |
Why?
| | Clinical Competence | 1 | 2019 | 882 | 0.110 |
Why?
| | Neuroimaging | 1 | 2014 | 249 | 0.100 |
Why?
| | Orthomyxoviridae | 1 | 2012 | 35 | 0.100 |
Why?
| | Temperature | 1 | 2015 | 564 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 207 | 0.100 |
Why?
| | Population Surveillance | 1 | 2014 | 385 | 0.090 |
Why?
| | Risk Assessment | 1 | 2019 | 2958 | 0.090 |
Why?
| | Risk Factors | 2 | 2020 | 8614 | 0.080 |
Why?
| | Animals | 3 | 2019 | 31565 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2017 | 4392 | 0.080 |
Why?
| | Young Adult | 4 | 2019 | 10444 | 0.080 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1468 | 0.070 |
Why?
| | Quality of Life | 1 | 2018 | 2343 | 0.070 |
Why?
| | California | 2 | 2019 | 351 | 0.070 |
Why?
| | Immunoglobulin G | 2 | 2019 | 766 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2272 | 0.060 |
Why?
| | Pregnancy | 1 | 2016 | 5499 | 0.060 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2024 | 38 | 0.060 |
Why?
| | Cluster Analysis | 2 | 2016 | 452 | 0.060 |
Why?
| | Computational Biology | 2 | 2019 | 528 | 0.050 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2024 | 192 | 0.050 |
Why?
| | Phylogeny | 2 | 2016 | 787 | 0.050 |
Why?
| | Adenoviridae | 1 | 2023 | 184 | 0.050 |
Why?
| | Immunologic Surveillance | 1 | 2022 | 19 | 0.050 |
Why?
| | Spatio-Temporal Analysis | 1 | 2021 | 25 | 0.050 |
Why?
| | Africa, Western | 1 | 2020 | 16 | 0.040 |
Why?
| | Living Donors | 1 | 2023 | 270 | 0.040 |
Why?
| | Technology | 1 | 2021 | 78 | 0.040 |
Why?
| | Child, Hospitalized | 1 | 2020 | 38 | 0.040 |
Why?
| | Patient Outcome Assessment | 1 | 2020 | 122 | 0.040 |
Why?
| | Consciousness Disorders | 1 | 2019 | 19 | 0.040 |
Why?
| | Picornaviridae | 1 | 2019 | 17 | 0.040 |
Why?
| | Encephalomyelitis, Acute Disseminated | 1 | 2019 | 13 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 316 | 0.040 |
Why?
| | Global Health | 1 | 2020 | 284 | 0.040 |
Why?
| | Neural Conduction | 1 | 2017 | 78 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 388 | 0.030 |
Why?
| | Atrophy | 1 | 2017 | 152 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2023 | 799 | 0.030 |
Why?
| | Sequence Homology | 1 | 2016 | 39 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 16 | 0.030 |
Why?
| | Antibodies, Viral | 1 | 2019 | 520 | 0.030 |
Why?
| | Guatemala | 1 | 2017 | 267 | 0.030 |
Why?
| | Open Reading Frames | 1 | 2016 | 117 | 0.030 |
Why?
| | RNA, Viral | 1 | 2019 | 565 | 0.030 |
Why?
| | Genome, Viral | 1 | 2016 | 118 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2017 | 618 | 0.030 |
Why?
| | Aftercare | 1 | 2017 | 186 | 0.030 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2016 | 148 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2017 | 251 | 0.030 |
Why?
| | Length of Stay | 1 | 2019 | 957 | 0.030 |
Why?
| | Cost of Illness | 1 | 2016 | 254 | 0.030 |
Why?
| | DNA, Viral | 1 | 2016 | 349 | 0.030 |
Why?
| | Brain Stem | 1 | 2014 | 94 | 0.030 |
Why?
| | Models, Biological | 1 | 2021 | 1611 | 0.030 |
Why?
| | Middle Aged | 3 | 2019 | 26605 | 0.030 |
Why?
| | Incidence | 1 | 2019 | 2314 | 0.030 |
Why?
| | Survival Rate | 1 | 2017 | 1638 | 0.030 |
Why?
| | Logistic Models | 1 | 2016 | 1829 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2764 | 0.020 |
Why?
| | Critical Illness | 1 | 2016 | 640 | 0.020 |
Why?
| | Autoantibodies | 1 | 2019 | 1347 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 3315 | 0.020 |
Why?
| | Aged | 2 | 2019 | 18969 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2537 | 0.020 |
Why?
|
|
Messacar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|